Ann: Appendix 4C - quarterly, page-19

Hello Friend,

the US patent in question relates to 2591 and has already been granted in the past; to date Neuren is negotiating with the audit commission, for a patent tolerance notice with slightly modified claims, which provide a little more protection in addition to the original patent, in particular separate claims for Angelman and Phelan-McDermid.otherwise,
the European patent for 2591 had the green light for the concession, but it is still hostage to the bureaucratic processes that must determine its officiality, which was expected by the end of June.
for the rest we have had in these days only retail activities, with the institutions that have been limited to the sole control and maintenance of set price levels.this means that the mutual founds present in the title, do not sell and buy for a long time and are probably set in the medium to long term, in order to discount future key events that today they know with certainty. all this results in limited market volatility and in full control, to the advantage of a course of the stock set as a level / event track.current goal is to consolidate the 2.50 quota.next objectives, first of all 2.80, secondly 3 $, which will be a fundamental technical level for a series of questions matured in the last 5 years.

hello and good WE